DiYES International School – Atorvastatin recall has impacted over 140,000 bottles of cholesterol medication distributed across the United States. The U.S. Food and Drug Administration issued the recall after Ascend Laboratories of New Jersey identified failed dissolution specifications in Atorvastatin Calcium tablets manufactured by Alkem Laboratories of India. The recall affects multiple tablet strengths including 10 mg, 20 mg, 40 mg, and 80 mg, packaged in 90-count, 500-count, and 1000-count bottles. Expiration dates for affected lots range from mid-2026 to February 2027.
The FDA classified this as a Class II recall, indicating temporary or medically reversible health consequences are possible, though serious effects are unlikely. Statins such as atorvastatin help millions of Americans reduce high cholesterol and prevent heart disease. Patients are urged to check their bottles for specific lot numbers and contact their pharmacies for replacements or guidance. Health experts stress that adherence to proper medication remains essential while monitoring recalled batches carefully.
The Atorvastatin recall includes numerous lot numbers across all affected strengths and bottle sizes. The 10 mg tablets have eight identified lot numbers per size, while 20 mg, 40 mg, and 80 mg tablets also include multiple affected lots. The recall covers tablets in 90-count, 500-count, and 1000-count bottles, with expiration dates spanning June 2026 through February 2027. Pharmacists and healthcare providers are instructed to remove affected bottles from shelves and replace them with unaffected medication. Patients should verify their bottle’s lot numbers and contact pharmacies for instructions on returning recalled medication. The FDA emphasizes that patients should not stop their cholesterol medication without consulting healthcare providers. Proper dissolution of atorvastatin ensures that the drug works effectively in the body to lower cholesterol. The recall underscores the importance of stringent quality control in pharmaceutical manufacturing.
The Atorvastatin recall specifically lists products including 10 mg, 20 mg, 40 mg, and 80 mg tablets. Each product comes in multiple lot numbers and packaging sizes. 10 mg tablets are recalled in 90-count, 500-count, and 1000-count bottles with lot numbers such as 25141249 expiring in February 2027. 20 mg tablets include lots 25140150 and 25140173 expiring in December 2026. 40 mg tablets cover lots 25140933 and 25140477 expiring from December 2026 to February 2027. 80 mg tablets include lots 25140249 and 25140247 expiring in December 2026. Patients can identify affected medication by comparing lot numbers on their bottles. Pharmacists are actively assisting patients in replacing recalled medication. Healthcare providers are also notifying patients with affected prescriptions. This extensive recall highlights the critical need for careful monitoring of pharmaceutical products.
The Atorvastatin recall creates risks because tablets may fail to dissolve properly, which could reduce their effectiveness. The FDA classifies this recall as Class II, meaning temporary or medically reversible health consequences can occur. Patients taking affected tablets should contact their healthcare providers for guidance and obtain replacement medication. Patients must not discontinue statins abruptly without professional advice. Statins such as atorvastatin help manage high cholesterol and prevent cardiovascular disease. Pharmacists actively replace recalled bottles and provide guidance on safe disposal. Patients should carefully check lot numbers on their medication. The recall also reminds patients to monitor the quality and storage of their medication. Health authorities emphasize that proper statin usage remains essential for long-term heart health.
The Atorvastatin recall has drawn attention from healthcare providers, pharmacies, and patients nationwide. Over 140,000 bottles are affected, prompting calls for heightened awareness about the recall. Many patients have expressed concern about the sudden disruption to their cholesterol management. Pharmacists are assisting patients with verification, replacement, and safe disposal of recalled medication. Health officials recommend monitoring expiration dates and lot numbers to ensure safe usage. The recall emphasizes the role of regulatory agencies in protecting public health. Patients should communicate with their doctors about any symptoms or concerns. The incident serves as a reminder of the importance of rigorous testing and quality control in pharmaceutical production. The recall continues to influence patient behavior and industry practices.
This article is sourced from usatoday and for more details you can read at diyesinternational
Writer: Sarah Azhari
Editor: Anisa
